New omicron sublineages surge, but Pfizer-BioNTech bivalent booster retains effectiveness Post author: Post published:October 30, 2023 Post category:uncategorized The efficacy of the bivalent Pfizer-BioNTech COVID-19 messenger ribonucleic acid (mRNA) vaccine BNT162b2 BA.4/5. You Might Also Like Groundbreaking technology converts cancer cells into normal cells December 23, 2024 Gut microbiota impacts pneumococcal vaccine response in immunodeficient individuals March 13, 2025 Bipartisan effort paves way for reviving shuttered hospitals in Georgia August 19, 2024